YHLO × Sanofi — Building a Type 1 Diabetes Ecosystem Together

On November 6, 2025, during the 8th China International Import Expo, YHLO joined hands with Sanofi to launch the China Type 1 Diabetes Ecosystem Co-construction Alliance, marking a new step toward proactive diabetes prevention and management.

As the world’s first and only therapy proven to delay the onset of Type 1 diabetes, Sanofi’s Tzield® (teplizumab) has officially entered China. In this partnership, YHLO contributes its diagnostic innovation and technical expertise to enable early screening, accurate classification, and precise intervention for Type 1 diabetes.

YHLO’s comprehensive testing portfolio empowers full-pathway management:
🔹 Adiponectin – early Type 2 diabetes risk prediction (5–10 years in advance)
🔹 GADA, IAA, IA-2A, ICA, ZnT8A – autoantibody panel for Type 1 diabetes detection
🔹 C-peptide, Insulin – β-cell function evaluation
🔹 PIFI platform – digital intelligence for smarter monitoring

This collaboration represents a milestone in diabetes care, integrating “diagnosis + therapy” to bring precision and prevention together — and to let science better serve health.